ArticleAnnals of surgical oncology2020
Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing.
Article in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Clinical management among individuals with variant of uncertain significance in hereditary cancer: A systematic review and meta-analysis.Clinical genetics · 2021Pooled it
- Genetic Testing for All Breast Cancer Patients: The GET FACTS Randomized Clinical Trial.JAMA network open · 2026Trial
- Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer by Age, Race, and Tumor Subtype.Annals of surgical oncology · 2026Article
- Bilateral Prophylactic and Contralateral Risk-Reducing Mastectomy in Women With Germline CDH1 Pathogenic or Likely-Pathogenic Variants.Journal of surgical oncology · 2026Review
- Risk-Reducing Interventions in Women With Pathogenic Variants in Breast Cancer Susceptibility Genes.JCO precision oncology · 2026Article
- Article
- Risk-Reducing Mastectomy inJournal of breast cancer · 2026Review
- Exploring the role of germline genetic testing in surgical decision making for early-stage invasive breast cancer: insights from a safety-net hospital.Journal of community genetics · 2025Article
- Surgical Choice among Women with a First Breast Cancer and Pathogenic Variants in Breast Cancer Genes.Annals of surgical oncology · 2025Article
- Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study.Breast cancer research and treatment · 2025Observational
- Impact of the American Society of Breast Surgeons' Guidelines on Genetic Testing and Contralateral Prophylactic Mastectomy Rates.Annals of surgical oncology · 2025Article
- Low temperature plasma suppresses proliferation, invasion, migration and survival of SK-BR-3 breast cancer cells.Molecular biology reports · 2023Article
- Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications.Current oncology reports · 2022Review
- Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes.Molecular genetics & genomic medicine · 2022Article
- Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants inThe breast journal · 2022Article
- The Virtual Scientific Sessions from the American Society of Breast Surgeons During the COVID-19 Pandemic.Annals of surgical oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAn increasing number of breast cancer patients are undergoing expanded genetic testing and are being identified as germline mutation carriers. We sought to determine rates of contralateral risk-reducing mastectomy (CRRM) in patients with various germline mutations. PATIENTS AND
methodsAll women ≥ 18 years of age with unilateral breast cancer who underwent multigene panel testing between January 1, 2014 and August 1, 2019 at our academic institution were identified. Demographic, tumor, and treatment variables were identified from the medical record. Multivariable analyses were performed to compare factors associated with performance of CRRM.
resultsWe identified 1613 patients, of whom 28.1% had a pathogenic variant and 40.1% had variants of uncertain significance (VUS). Overall, 420 patients (26.0%) underwent a CRRM. On multivariable analysis, factors associated with CRRM included age < 50 years (OR 3.8, 95% CI 3.0, 5.0), race (OR 0.5, 95% CI 0.3, 0.7 and OR 0.4, 95% CI 0.2, 0.7 for Black and Asian women, respectively, versus White women), and the presence of any germline mutation or VUS (OR 13.2, 95% CI 8.7, 20.2 for BRCA1/2; OR 3.9, 95% CI 2.7, 5.8 for non-BRCA germline mutation; and OR 1.8, 95% CI 1.3, 2.6 for VUS).
conclusionsIn breast cancer patients who undergo multigene panel testing, a sizeable number of women with pathogenic non-BRCA germline findings are opting for CRRM. Given that the risk of contralateral breast cancer in women with most pathogenic mutations other than BRCA1/2 remains poorly characterized, these data have implications for risk counseling and for ascertaining the true risks of contralateral breast cancer in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.